Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 17;14(4):427.
doi: 10.3390/jpm14040427.

Long-Term Outcomes of Patients with Biologically Treated Psoriatic Arthritis and Atopic Dermatitis-A Single-Center Experience

Georgiana Strugariu  1   2 , Cristina Pomîrleanu  1   2 , Mara Russu  1   2 , Alexandra Popescu  1 , Luiza Andreea Petrariu  2 , Eugen Ancuta  3 , Rodica Chirieac  4 , Doinița Temelie-Olinici  5 , Codrina Ancuța  1   2
Affiliations

Long-Term Outcomes of Patients with Biologically Treated Psoriatic Arthritis and Atopic Dermatitis-A Single-Center Experience

Georgiana Strugariu et al. J Pers Med. .

Abstract

(1) Background: Although the association between psoriasis and atopic dermatitis (AD) is reported in the literature, scarce data are known about the efficacy of biologic therapy (including TNF and IL-17 inhibitors) in patients with psoriatic arthritis (PsA) and concomitant AD. (2) Objective: We aimed to explore AD in patients with PsA undergoing biologics for their active disease, focusing on prevalence and clinical and potential therapeutic implications. (3) Material and methods: We performed a retrospective analysis of 64 patients with PsA receiving various biological agents, followed-up in an academic outpatient rheumatology department up to 10 years. (4) Results: Atopic diseases were reported in about one third of cases, with a higher incidence of AD (10 cases; 52.6%) vs. atopic rhinitis (6 cases; 31.6%) and allergic asthma (3 cases; 15.8%). Three morphological patterns of AD were recognized including chronic prurigo (3 cases), a chronic lichen simplex (1 case), and eczemas (6 cases). All PsA with concomitant AD displayed a late onset of skin atopy (in their adult life) and demonstrated a specific profile (younger), from urban settings, equally distributed among genders, and requiring switching to a higher number of biologics to achieve disease control. (5) Conclusion: PsA and AD may coexist, requiring special attention when selecting the optimal biologic agent.

Keywords: IL-17 inhibitors; TNF inhibitors; atopic dermatitis; biologic therapy; psoriasis; psoriatic arthritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flow-chart of patients with PsA enrolled; * diagnosed according to 2006 CASPAR criteria; ** loss of evidence or declined participation in study; *** patients with concomitant allergic asthma and allergic rhinitis.
Figure 2
Figure 2
Patients with and without atopy in our cohort of PsA.
Figure 3
Figure 3
Distribution of atopic disorders in PsA with atopy subgroup; AD, atopic dermatitis; AR, allergic rhinitis; AA, allergic asthma; pts, patients.
Figure 4
Figure 4
Morphologic phenotypes of atopic dermatitis in patients with PsA biologically treated.
Figure 5
Figure 5
Non-responder rate between 2013 and 2023 to more than one iTNF in our study groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Menegatti S., Guillemot V., Latis E., Yahia-Cherbal H., Mittermüller D., Rouilly V., Mascia E., Rosine N., Koturan S., Millot G.A., et al. Immune response profiling of patients with spon-dyloarthritis reveals signalling networks mediating TNF-blocker function in vivo. Ann. Rheum. Dis. 2021;80:475–486. doi: 10.1136/annrheumdis-2020-218304. - DOI - PMC - PubMed
    1. Stolwijk C., Boonen A., van Tubergen A., Reveille J.D. Epidemiology of spondyloarthritis. Rheum. Dis. Clin. N. Am. 2012;38:441–476. doi: 10.1016/j.rdc.2012.09.003. - DOI - PMC - PubMed
    1. Tillett W., Costa L., Jadon D., Wallis D., Cavill C., McHUGH J., Korendowych E., McHUGH N. The ClASsification for Psoriatic ARthritis (CASPAR) Criteria—A Retrospective Feasibility, Sensitivity, and Specificity Study. J. Rheumatol. 2012;39:154–156. doi: 10.3899/jrheum.110845. - DOI - PubMed
    1. Zabotti A., De Lucia O., Sakellariou G., Batticciotto A., Cincinelli G., Giovannini I., Idolazzi L., Maioli G., Tinazzi I., Aletaha D., et al. Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis. Rheumatol. Ther. 2021;8:1519–1534. doi: 10.1007/s40744-021-00378-w. - DOI - PMC - PubMed
    1. Gill T., Asquith M., Rosenbaum J.T., Colbert R.A. The intestinal microbiome in spondyloarthritis. Curr. Opin. Rheumatol. 2015;27:319–325. doi: 10.1097/BOR.0000000000000187. - DOI - PMC - PubMed